Loading...
•
Jun 30, 2023
Insulet Q2 2023 Earnings Report
Insulet reported a revenue increase of 32% year-over-year.
Key Takeaways
Insulet Corporation reported a strong second quarter with a 32.4% increase in revenue, driven by Omnipod demand. The company commercially launched Omnipod 5 in the UK and submitted the Omnipod 5 iOS App to the FDA.
Second quarter revenue increased by 32.4% to $396.5 million.
U.S. Omnipod revenue increased by 40.9%.
International Omnipod revenue increased by 16.0%.
Operating income was $31.1 million, or 7.8% of revenue, compared to an operating loss in the prior year.
Insulet
Insulet
Insulet Revenue by Segment
Revenue by Segment
U.S. Omnipod Revenue
CapyFin.comInternational Omnipod Revenue
CapyFin.comDrug Delivery Revenue
CapyFin.com Forward Guidance
The Company expects revenue growth of 18% to 21% for the quarter ending September 30, 2023.
Positive Outlook
- Total Omnipod revenue growth of 20% to 23%.
- U.S. Omnipod revenue growth of 27% to 30%.
- International Omnipod revenue growth of 2% to 5%.
- Drug Delivery revenue decline of (30)% to (25)%.
- For the year ending December 31, 2023, the Company is raising its expected revenue growth of 22% to 25% (previously 18% to 22%).
Challenges Ahead
- International Omnipod of 7% to 10% (previously 6% to 10%)
- Drug Delivery of (50)% to (45)% (previously (55)% to (45)%)
Revenue & Expenses
Visualization of income flow from segment revenue to net income